Drug News

Chemotherapy Induced Peripheral Neuropathy Treatment Market Projected to Hit $2.25 Billion by 2028

The chemotherapy-induced peripheral neuropathy (CIPN) treatment market is experiencing robust growth, with projections indicating a rise to $2.25 billion by 2028. This growth is attributed to advancements in cancer treatment, expanding options for chemotherapy, limited alternatives for treatment, an increase in cancer incidences, and progress in neurological research.

Recent years have witnessed significant expansion, with the market size growing from $1.54 billion in 2023 to $1.65 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The anticipated compound annual growth rate (CAGR) of 8.0% is expected to drive the market to $2.25 billion by 2028. Key factors contributing to this growth include the development of targeted therapies, the emergence of neuroprotective agents, implementation of integrated care pathways, adoption of patient-centered care models, and regulatory support.

The increasing prevalence of cancer globally is a significant driver for the growth of the chemotherapy-induced peripheral neuropathy treatment market. Cancer often necessitates chemotherapy treatment, which can lead to chemotherapy-induced peripheral neuropathy (CIPN). With rising cancer cases worldwide, particularly evident in reports like the increase in newly diagnosed liver cancer cases in the United States, the demand for CIPN treatment is set to surge.

Furthermore, an upsurge in healthcare spending is fueling market growth, with healthcare expenditures aimed at supporting treatments for CIPN. For example, the United States witnessed a 2.7% increase in health spending in 2021, reaching $4.3 trillion, which bolsters the demand for CIPN treatment options.

Product innovation is a prominent trend in the market, with companies focusing on developing novel products to enhance efficacy. Notable developments include AlgoTx’s FDA approval of their Investigational New Drug Application (IND) for ATX01, a Phase 2 candidate for chemotherapy-induced peripheral neuropathy. Fast-track designation from the FDA underscores the potential significance of such treatments in addressing unmet medical needs.

Moreover, technological advancements, particularly the incorporation of quell technology, are driving innovation in the chemotherapy-induced peripheral neuropathy treatment market, aiding companies in fortifying their market standing.

The primary drug categories for CIPN treatment include nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidants, and others. These treatment modalities, available through various distribution channels such as hospital pharmacies, retail outlets, and online platforms, cater to end-users including hospitals, research institutes, and specialty clinics.

The report provides comprehensive insights into the chemotherapy-induced peripheral neuropathy treatment market, covering market characteristics, size, growth, segmentation, regional and country breakdowns, competitive landscape, trends, and strategies. With a focus on both historic and forecast data, the report offers valuable information to stakeholders navigating the evolving landscape of CIPN treatment.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker